Allarity Advances Stenoparib Phase 3 API Manufacturing, On Track for Q3 2026
Allarity Therapeutics’ Phase 3 stenoparib API manufacturing campaign is on track to finish by the third quarter of 2026, with all production payments completed and no further cash outlays anticipated. This operational milestone leverages FDA Fast Track designation and supports preparation for a potential pivotal trial in advanced ovarian cancer.
1. Manufacturing Campaign Progress
Allarity has initiated its Phase 3 active pharmaceutical ingredient manufacturing campaign for stenoparib at a European CDMO operating under GMP standards. The campaign is scheduled for completion by the third quarter of 2026, aligning supply readiness with the planned pivotal trial timeline.
2. Financial Implications
The company has finalized all manufacturing-related payments, ensuring no additional cash outlays are required for the API campaign. This completion supports a more stable cash runway and removes near-term capital expenditure uncertainties tied to drug supply.
3. Clinical and Regulatory Context
Stenoparib holds FDA Fast Track designation based on previous data showing extended overall survival in advanced, platinum-resistant ovarian cancer patients. The manufacturing milestone positions Allarity to advance into a pivotal-stage trial aimed at securing FDA approval for this dual PARP/WNT pathway inhibitor.